• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CARBOPLATIN Drug Record

  • Summary
  • Interactions
  • Claims
  • CARBOPLATIN chembl:CHEMBL1351 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PARAPLATIN
    NSC-241240
    CARBOPLATIN
    JM-8
    NSC-201345
    CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
    CBDCA
    CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
    CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
    drugbank:00958
    chembl:CHEMBL1351
    rxcui:40048
    chemidplus:41575-94-4
    pubchem.compound:10339178

    Drug Info:

    (6 More Sources)

    Publications:

    Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
    Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
    He YJ et al., 2016, Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial., Pharmacogenomics J
    Ishimoto et al., 2002, Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli., Pharmacogenetics
    Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Fader AN et al., 2018, Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu., J Clin Oncol
    Koivusalo et al., 2002, Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand., Cancer Res.
    Westfall et al., 2005, Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment., Mol. Cancer Ther.
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Pertusini et al., 2001, Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy., Blood
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
    Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
    Leijen et al., 2016, Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months., J. Clin. Oncol.
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
    Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.
    Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
    Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
    Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
    Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
    Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
    Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
    Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
    Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
    Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
    Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
    Ando et al., 1998, EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway., Jpn. J. Cancer Res.
    Flamm et al., Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin., Anticancer Res.
    Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev
    Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
    Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
    Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
    Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
    Tonsing-Carter et al., 2015, Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model., Mol. Cancer Ther.
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
    Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE
    Reles et al., 2001, Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer., Clin. Cancer Res.
    Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.
    Bachmann HS et al., 2015, The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients., Br J Clin Pharmacol
    Cui LH et al., 2011, Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC., Pharmacogenomics
    Patiño-García A et al., 2009, Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression., J Pediatr
    Oizumi S et al., 2012, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial., Oncologist
    Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.
    Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
    Goto K et al., 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer., J Thorac Oncol
    Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
    Maemondo et al., 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N. Engl. J. Med.
    Mitsudomi et al., 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Lancet Oncol.
    Mok et al., 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N. Engl. J. Med.
    Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi
    Oguri et al., Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients., Anticancer Res.
    Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
    Yamasaki S et al., 2015, UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan., Ann Hematol
    Xu X et al., 2012, Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients., Clin Exp Pharmacol Physiol
    Ekhart C et al., 2008, Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin., Pharmacogenet Genomics
    Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
    Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
    Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
    Gandara et al., 2009, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics., J. Clin. Oncol.
    Sato Y et al., 2011, Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel., J Thorac Oncol
    Park HS et al., 2016, Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy., Pharmacogenet Genomics
    Mbatchi LC et al., 2015, Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination., Pharmacogenomics
    Xu X et al., 2013, The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients., Lung Cancer
    Santibáñez M et al., 2013, The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer., Pharmacogenet Genomics
    Sheffield et al., 2015, Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing., PLoS ONE
    Kaklamani et al., 2015, Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)., Breast Cancer Res. Treat.
  • CARBOPLATIN   MTR

    Interaction Score: 1.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 21605004 19159907


    Sources:
    PharmGKB

  • CARBOPLATIN   MAD1L1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23407047


    Sources:
    PharmGKB

  • CARBOPLATIN   EIF3A

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23127338


    Sources:
    PharmGKB

  • CARBOPLATIN   DSCAM

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21079520


    Sources:
    PharmGKB

  • CARBOPLATIN   SLC31A1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22725681


    Sources:
    PharmGKB

  • CARBOPLATIN   C6ORF15

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   MUCL3

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   DOCK8

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   MSH5

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   ETS2

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   ATAT1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   PPP1R18

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   CDSN

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   XYLT2

    Interaction Score: 0.78

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   ATP7B

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15213293 26194361


    Sources:
    NCI PharmGKB

  • CARBOPLATIN   ERCC1

    Interaction Score: 0.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182


    Sources:
    PharmGKB

  • CARBOPLATIN   PRRC2A

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   HCP5

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   GPX5

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CARBOPLATIN   RNF8

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • CARBOPLATIN   TRIM5

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CARBOPLATIN   GCLC

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11911273


    Sources:
    NCI

  • CARBOPLATIN   SERPINA5

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   FNTB

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26033044


    Sources:
    PharmGKB

  • CARBOPLATIN   SOX10

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • CARBOPLATIN   PSORS1C1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   NF2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25798586


    Sources:
    CIViC

  • CARBOPLATIN   BARD1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • CARBOPLATIN   TP73

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12499281


    Sources:
    NCI

  • CARBOPLATIN   ACSS2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CARBOPLATIN   ATP7A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14676106


    Sources:
    NCI

  • CARBOPLATIN   MTHFR

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29662106 27995989 21605004 20634689 19307503 19159907


    Sources:
    PharmGKB

  • CARBOPLATIN   MAP3K1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CARBOPLATIN   ERCC2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19470925


    Sources:
    CIViC

  • CARBOPLATIN   XRCC1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    CIViC

  • CARBOPLATIN   SLC19A1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    PharmGKB

  • CARBOPLATIN   HLA-C

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   SMAD4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CARBOPLATIN   SLCO1B3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26641474 26267044


    Sources:
    PharmGKB

  • CARBOPLATIN   GSR

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26194361


    Sources:
    PharmGKB

  • CARBOPLATIN   BRCA2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Veliparib + Carboplatin
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    25847936


    Sources:
    JAX-CKB CIViC

  • CARBOPLATIN   CDKN1A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12168940


    Sources:
    NCI

  • CARBOPLATIN   RAF1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CARBOPLATIN   GSTT1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CARBOPLATIN   CDKN2A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CARBOPLATIN   SERPINC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   NRG1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23390248


    Sources:
    CIViC

  • CARBOPLATIN   GSTP1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12360105 25010864


    Sources:
    NCI CIViC

  • CARBOPLATIN   BRCA1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + VX-970
    Indication/Tumor Type ovarian cancer
    Response Type sensitive

    PMIDs:
    25847936 27998224 25824335 21135055


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • CARBOPLATIN   BCL2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    ClearityFoundationBiomarkers PharmGKB

  • CARBOPLATIN   ERBB3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039


    Sources:
    PharmGKB

  • CARBOPLATIN   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083


    Sources:
    CIViC PharmGKB

  • CARBOPLATIN   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy XL147 + Carboplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    26307133 21216929 16043828 27998224 25637314 22139083


    Sources:
    JAX-CKB CIViC

  • CARBOPLATIN   BIRC5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15347474


    Sources:
    NCI

  • CARBOPLATIN   UGT1A1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25055799


    Sources:
    PharmGKB

  • CARBOPLATIN   VEGFA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26194361


    Sources:
    PharmGKB

  • CARBOPLATIN   MCL1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10081494


    Sources:
    NCI

  • CARBOPLATIN   NRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • CARBOPLATIN   PIK3CA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy XL147 + Carboplatin + Paclitaxel
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    16275998 21216929


    Sources:
    JAX-CKB NCI PharmGKB

  • CARBOPLATIN   CDK2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26006067


    Sources:
    CIViC

  • CARBOPLATIN   PDGFRA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Clinical Study
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CARBOPLATIN   PTEN

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25672916


    Sources:
    CIViC PharmGKB

  • CARBOPLATIN   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • CARBOPLATIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22901187


    Sources:
    PharmGKB

  • CARBOPLATIN   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30071039 29584549


    Sources:
    CIViC PharmGKB

  • CARBOPLATIN   SCN10A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26194361


    Sources:
    PharmGKB

  • CARBOPLATIN   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26179145


    Sources:
    PharmGKB

  • CARBOPLATIN   OPRM1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • CARBOPLATIN   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CARBOPLATIN   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Carboplatin
    Indication/Tumor Type ovarian cancer
    Response Type predicted – resistant

    PMIDs:
    26494859 25567130 25658463 27998224 11595686


    Sources:
    JAX-CKB CIViC

  • CARBOPLATIN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11157479


    Sources:
    NCI

  • CARBOPLATIN   KAT2A

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   APEX1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18854779


    Sources:
    PharmGKB

  • CARBOPLATIN   USP1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   POLK

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   HSD17B10

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   MAPT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: CBDCA

    • Version: 14-September-2017

    Alternate Names:
    C1282 NCI drug code

    Drug Info:

    Publications:
    Oguri et al., Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients., Anticancer Res.

  • NCI: CARBOPLATIN

    • Version: 14-September-2017

    Alternate Names:
    C1282 NCI drug code

    Drug Info:

    Publications:
    Pertusini et al., 2001, Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy., Blood
    Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.
    Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi

  • JAX-CKB: Carboplatin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
    Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.

  • PharmGKB: carboplatin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res

  • CIViC: CARBOPLATIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.

  • DTC: CARBOPLATIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1351 ChEMBL Drug ID

    Drug Info:

    Publications:

  • DTC: PARAPLATIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL288376 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Carboplatin

    • Version: 2020.06.01

    Alternate Names:
    D0X7HM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1351

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: CARBOPLATIN

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21